Liangsu Wang is a biopharmaceutical leader with more than 25 years of experience advancing numerous drug programs from discovery to clinical development across multiple therapeutic areas. Most recently, she was the founder and managing director of BioSage Advisors, LLC, where she advised biopharma and VC firms on scientific and business strategy, including indication selection, portfolio prioritization, strategic partnership and licensing, capital fundraising and asset spin-offs. Previously, Liangsu was Vice President and Therapeutic Area Head of External Innovation at Johnson & Johnson, where she led partnership and licensing strategy across cardiometabolic, pulmonary, and ophthalmic therapeutic areas in Asia-Pacific, West North America, New Zealand, and Australia. Prior to Johnson & Johnson, Liangsu served as Vice President and Head of Biology at Morphic Therapeutic, where she established the company’s scientific strategy, built the biology team and helped develop a pipeline in inflammatory bowel disease (IBD) and fibrosis. She played a key role in Morphic’s successful series B financing and 2019 IPO, and initiated the MORF-057 program, delivering IND readiness, which ultimately contributed to the company’s $3.2 billion acquisition by Eli Lilly in 2024. Earlier in her career, she held senior leadership roles at Merck, including Executive Director and Head of Diabetes and NASH Discovery Research.

Liangsu holds a Ph.D. from University of Calgary and a BS from Fudan University.